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Sudden Cardiac Death 
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and Peter Magnusson
Abstract
Dilated cardiomyopathy (DCM) is characterized by the phenotype of a dilated 
left ventricle with systolic dysfunction. It is classified as hereditary when it is 
deemed of genetic origin; more than 50 genes are reported to be related to the 
condition. Symptoms include, among others, dyspnea, fatigue, arrhythmias, and 
syncope. Unfortunately, sudden cardiac death may be the first manifestation of the 
disease. Risk stratification regarding sudden death in hereditary DCM as well as 
preventive management poses a challenge due to the heterogeneity of the disease. 
The purpose of this chapter is to present the epidemiology, risk stratification, and 
preventive strategies of sudden cardiac death in hereditary DCM.
Keywords: cardiomyopathy, dilated cardiomyopathy, heart failure, implantable 
cardioverter defibrillator, risk stratification
1. Introduction
Cardiomyopathies are categorized based on their phenotype. In that context, 
dilated cardiomyopathy (DCM) is characterized by a dilated left ventricle (LV), 
typically with thin walls, and systolic dysfunction (Figure 1). Sometimes the 
dysfunction is not limited to the left ventricle but also affects the right ventricle. It is 
estimated that approximately 1 in 2500 people suffer from DCM [1]. The causative 
pathways are often complex, and several risk factors work together. In the vast 
majority of patients, there is a history of hypertension. Other well-known etiolo-
gies are myocarditis, chemotherapy, toxins, radiation, and coronary artery disease. 
However, when a causative reason for the dilation of the heart cannot be identified, 
DCM is considered idiopathic. About 20–50% of idiopathic DCM is considered 
to be of a genetic origin, being consequently hereditary [2]. Interestingly, only in 
30–40% of cases of familial DCM can a specific gene be identified [3].
In hereditary DCM, there is variability among phenotypes, and the manifesta-
tion of LV dysfunction is heterogeneous. More than 50 genes are associated with the 
disease [4] (Table 1). Many of the gene mutations responsible for DCM affect the 
cell structure called sarcomere, which is involved in cardiac contractility. That is why 
some of those genes may be responsible for the development of hypertrophic car-
diomyopathy as well. In 20% of the cases of hereditary DCM, mutations of the titin 
(TTN) gene are found, which encodes the protein titin found in the sarcomere [5].
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The inheritance pattern is autosomal dominant in the vast majority of the cases, 
which means that an individual has a 50% chance to inherit the gene if one of the 
parents carries it. In other cases, the pattern is autosomal recessive, which means 
that if both parents are affected, there is a 25% chance of inheriting the disease 
genotype. X-linked patterns, in which the gene is inherited through an X chromo-
some, have also been reported. In some cases, it is possible that the carrier may not 
develop the phenotype of the disease due to variable penetrance of the disease.
Inherited DCM is defined by (a) the presence of two or more affected individu-
als in a single family who fulfill DCM criteria; fractional shortening <25% and/or  
ejection fraction <45% and left ventricular end diastolic diameter > 117% of the 
upper reference level corrected for age and body surface area based on Henry’s 
formula or (b) the presence of a first-degree relative with unexplained sudden death 
before the age of 35 years [6].
Symptoms of DCM are due to ventricular dysfunction and compensatory left 
ventricular remodeling as well as the involvement of the electrical conduction sys-
tem of the heart [7]. Symptoms vary among patients, even if they are members of 
Figure 1. 
Normal and dilated left ventricle in parasternal short-axis view.
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the same family [5]. Symptoms can occur at any age; typically, they first appear in 
mid-adulthood. Patients often report breathlessness, swelling of the legs, fatigue, 
chest pain, and arrhythmias, ranging from palpitations and syncope to fatal 
Gene Cellular structure
ABCC9 Calcium/sodium handling
ACTC1 Sarcomere and cytoskeleton
ACTN2 Sarcomere and cytoskeleton
ANKRD1 Sarcomere and transcription factor
BAG3 Sarcomere
CRYAB Cytoskeleton
CSRP3 Sarcomere and cytoskeleton
DES Cytoskeleton
DMD Cytoskeleton
DSG2 Desmosome
EYA4 Other
FLNC Cytoskeleton
GATAD1 Other
LAMA4 Extracellular matrix proteins
LCB3 Cytoskeleton
LMNA Nuclear envelope
MYBPC3 Sarcomere
MYH6 Sarcomere
MYH7 Sarcomere
MYPN Cytoskeleton
PLN Calcium/sodium handling
PSEN1 Other
PSEN2 Other
RBM20 Other
SCN5A Calcium/sodium handling
SGCD Cytoskeleton
TAZ Other
TCAP Sarcomere and cytoskeleton
TMPO Nuclear envelope
TNNC1 Sarcomere
TNNI3 Sarcomere
TNNT2 Sarcomere
TPM1 Sarcomere
TTN Sarcomere
VCL Sarcomere and cytoskeleton
Table 1. 
The main genes associated with hereditary dilated cardiomyopathy and the cellular structure that they regulate.
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arrhythmias that cause SCD. Unfortunately, SCD is sometimes the first manifesta-
tion of the disease.
2. Sudden cardiac death in hereditary DCM
2.1 Definition of sudden cardiac death
Sudden cardiac death (SCD) is defined as the sudden and unexpected death of a 
person who was otherwise stable prior to the event [8]. If the death is witnessed and 
occurs within 1 hour of onset of symptoms, it is classified as SCD. If the sudden and 
unexpected death is not witnessed, then SCD is declared if it occurs within 24 hours 
of the person last being seen alive and well.
2.2 Mechanisms
In the case of hereditary cardiomyopathies, such as DCM, SCD occurs due to 
the development of fatal ventricular arrhythmias: ventricular tachycardia (VT) 
and ventricular fibrillation (VF) are most common, but prolonged bradycardia 
does occur. Possible underlying mechanisms for the initiation of a fatal re-entry 
arrhythmia in a DCM patient may include: (a) conduction block caused by a reduc-
tion of myocytes and hypertrophy and (b) continuous re-entry regeneration due to 
increased fibrosis, interstitial, and perivascular as well as post-necrosis fibrosis  
[9, 10]. Non re-entry mechanisms, such as focal automaticity, electrolyte distur-
bances, and stretch-induced arrhythmias, also contribute to the presentation of 
arrhythmias [10]. In particular, focal automaticity predisposes a patient to nonsus-
tained VT (NSVT) [11].
2.3 Epidemiology
DCM ranks third as the cause of SCD among cardiomyopathies, after arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) and hypertrophic cardiomy-
opathy. SCD accounts for roughly a third of all-cause mortality among hereditary 
DCM patients. Rates of SCD vary among the patients in regard to their New York 
Heart Association (NYHA) functional status (Table 2). Notably, in patients with 
NYHA class I and II, 50–60% of deaths are classified as sudden, while in NYHA 
class IV patients, only 20–30% of deaths are sudden [10]. This is explained by the 
fact that in NYHA class IV, most patients die from progressive heart failure [12]. In 
most cases, potentially fatal arrhythmias present in a setting of systolic ventricular 
dysfunction, although the proportion of SCD is higher among patients with lower 
NYHA status. However, there is a subset of patients (reported to vary from 2% to 
one third of the DCM population) who present early in the disease course with 
NYHA Risk of SCD
Class I 50–60%
Class II 50–60%
Class III 20–30%
Class IV 20–30%
Table 2. 
Risk of sudden cardiac death as a proportion of overall mortality according to New York Heart Association 
classification.
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life-threatening arrhythmias or unexplained syncope that are not related to the 
severity of LV dysfunction [13, 14]. This specific entity is referred to as arrhyth-
mogenic DCM (AR-DCM). Patients who suffer from AR-DCM, compared to 
other DCM patients, have a higher risk of experiencing major arrhythmic events 
and SCD. Thus, a family history of SCD in an AR-DCM patient results in a higher 
burden of life-threatening arrhythmias and a higher risk of SCD [7]. It is important 
to mention that DCM patients, due to their high incidence of atrial fibrillation, also 
have a higher risk for ischemic stroke. However, it should be noted that if a cause of 
death other than arrhythmia is confirmed, the death will not be classified as sudden.
2.4 Risk stratification
It is crucial to identify patients at high risk of a fatal arrhythmia. There are clues 
in the clinical history, electrocardiographic, imaging characteristics, and specific 
genetic features that need to be taken into account. Factors such as QRS duration, 
QT-interval dispersion, and T-wave alternans have been suggested as risk markers 
[15]. A considerable burden of ventricular arrhythmias (runs of VT) is usually pres-
ent in a setting of advanced ventricular dysfunction with left ventricular ejection 
fraction (LVEF) <25%, which is a validated risk factor. Survived cardiac arrest and 
sustained ventricular tachycardia with hemodynamic compromise imply a high risk 
of recurrent arrhythmia and are classified as secondary prevention for an implant-
able cardioverter defibrillator (ICD) [16]. Unexplained syncope may be secondary 
to arrhythmia and constitutes a risk factor [15]. In the Marburg Cardiomyopathy 
study (MACAS), which excluded patients with a history of sustained VT or VF, 
unexplained syncope within the previous 12 months, and amiodarone therapy, 
it was shown that a low LVEF (<30%) was the only independent factor for major 
arrhythmic events. Patients with NSVT and patients who were not on beta-blockers 
upon enrollment also run a high risk for ventricular arrhythmias. Thus, the com-
bination of documented NSVT on Holter monitoring with a low LVEF (<30%) 
increased the arrhythmic risk by eight-fold [17]. Family history of SCD, defined as 
SCD in a first degree relative <40 years of age or SCD in a relative with confirmed 
DCM at any age, is also an established risk factor.
Factors associated with a high risk of arrhythmias
Clinical Low LVEF (<25–30%)
Absence of beta-blockers
AR-DCM
Family history of SCD
Ambulatory QRS duration
QT dynamicity
T-wave alternans
NSVT on Holter monitoring
Imaging Midwall late gadolinium enhancement
Impaired global longitudinal strain
Mechanical dispersion
Genetic Desmosomal mutations
LMNA mutation
SCN5A mutation
FLNC mutation
RBM20 mutation
PLN mutation
Table 3. 
Factors associated with a high risk of life-threatening arrhythmias.
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2.5 Imaging
Imaging can be used to predict arrhythmia risk. In cardiac magnetic resonance 
imaging, midwall late gadolinium enhancement (LGE) can detect fibrosis. Even if 
magnetic resonance imaging is not able to detect fibrosis, it may still be found by 
advanced T1 mapping techniques before and after gadolinium infusion. This is a 
prominent finding due to the fact that it corresponds to macroscopic midmyocardial 
fibrosis on postmortem examination [18]. In echocardiography, an impaired global 
longitudinal strain, a marker of myocardial regional contractility, may reflect myo-
cardial fibrosis [19]. It has been demonstrated that an impaired global longitudinal 
strain is associated with increased arrhythmic events [20]. A predictor of arrhyth-
mias is also mechanical dispersion, which is defined as the standard deviation of the 
time to peak negative strain among the different myocardial segments [20].
2.6 Mutations associated with SCD
Regarding genetic factors, DCM patients who carry a desmosomal or LMNA 
(lamin A/C) mutation run a higher risk of life-threatening ventricular arrhythmias 
and SCD, regardless of their LVEF. Patients who carry the LMNA gene, which 
encodes the type V intermediate filament protein, tend to have more life-threaten-
ing arrhythmias compared to other variant carriers and variant-negative patients  
[21, 22]. LMNA mutations are associated with high morbidity and mortality and 
with a high clinical penetrance [23]. For the LMNA carriers, various risk factors 
have been identified. These include NSVT during electrocardiogram monitoring, 
truncating mutations, LVEF <45–50%, and male sex [24, 25]. More recently, 1st 
degree AV block has been identified as another risk factor in LMNA carriers [26]. 
Desmosomal gene mutations are present in around 3% of DCM patients. They 
are also frequent in ARVC patients, creating a genotype overlap between the two 
cardiomyopathies. They have been associated with a high risk of potentially fatal 
arrhythmias, independently from the LVEF [21]. The SCN5A (sodium voltage-gated 
channel alpha subunit 5) gene, which provides instructions for making sodium 
channels, is also associated with conduction defects and ventricular arrhythmias 
[10]. Also associated with a higher risk of arrhythmic events are mutations in 
the FLNC gene, which encodes filamin proteins; the RNA-binding motif protein 
20 gene (RBM20 gene), which encodes a protein that regulates splicing and the 
phospholamban (PLN) gene, which encodes a protein that inhibits a sarcoplasmic 
ATPase [21, 27]. In a 2019 study, it was demonstrated that RBM20 mutation carri-
ers were more likely to have NSVT and sustained VT than idiopathic DCM cohorts 
[28]. The AR-DCM phenotype is associated with a high risk of fatal arrhythmias. 
Spezzacatene et al. identified the AR-DCM phenotype as well as a family history of 
SCD or sustained VT/VF as the only early significant predictors for SCD or sus-
tained VT/VF in the overall DCM population. Interestingly, the AR-DCM pheno-
type is associated with a higher risk of arrhythmias, irrespective of LV dilatation 
and dysfunction, which is in contradiction to the general DCM population, where a 
low LVEF is associated with a higher arrhythmic risk [14]. However, AR-DCM is not 
associated with a poorer prognosis due to non-arrhythmic events, including heart 
failure [14].
2.7 Preventive management
Most DCM patients present with heart failure and are at a high risk of death. 
The primary management of such patients lies in the stabilization of progressive 
heart failure. Drugs like renin-angiotensin-aldosterone system (RAAS) antagonists 
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and beta-blockers are first-line management in patients with DCM and reduce the 
risk of SCD by preventing ventricular remodeling. Angiotensin converting enzyme 
inhibitors (ACEs)/angiotensin receptor blockers (ARBs), mineralocorticoid 
receptor antagonists (MRAs), and beta-blockers are recommended, unless contra-
indicated or not tolerated. Furthermore, the combination of sacubitril/valsartan 
has been shown to be superior to ACE inhibitors and tends to replace them in the 
treatment of patients who are still symptomatic patients despite optimal medical 
treatment [16]. The anti-diabetic drug, dapagliflozin, seems to reduce the risk of 
worsening heart failure and death in patients with a reduced LVEF as well, regard-
less of the presence of diabetes mellitus, as proven in Dapagliflozin in Patients with 
Heart Failure and Reduced Ejection Fraction (DAPA-HF) study [29]. In NYHA IV 
patients, asystolic arrest and pulseless electrical activity are a frequent cause of 
death [10]. Cardiac resynchronization therapy (CRT) and CRT with defibrillator 
(CRT-D) treatment also has a place in both symptomatic treatment and preventive 
management of such patients.
Arrhythmia management in hereditary DCM patients follows the general recom-
mendations as SCD prevention in patients with reduced LVEF (<35%) [7]. Thus, 
patients with diagnosed DCM must be carefully evaluated for ventricular arrhyth-
mias. Regarding drug management, amiodarone has not been proven to further 
reduce overall mortality or arrhythmic risk in the Amiodarone versus Implantable 
Defibrillator (AMIOVIRT) study, which showed that DCM patients who were on 
amiodarone did not have a statistically significant difference in terms of survival, 
compared to patients who received an ICD [30]. However, in the Sudden Cardiac 
Death in Heart Failure trial (SCD-HeFT) which enrolled patients with an LVEF 
<35% and NYHA II or III despite optimal medical therapy and compared ICD 
insertion vs. amiodarone vs. placebo, ICD therapy conferred a significant benefit 
in patients in NYHA class II, but not in class III. Furthermore, amiodarone, when 
compared to placebo therapy, showed no benefit in NYHA Class II patients and 
decreased survival among NYHA Class III patients. Results varied among NYHA 
classes but did not vary between heart failure of ischemic or nonischemic origin 
[31]. The Defibrillator Implantation in Patients with Nonischemic Systolic Heart 
Failure (DANISH) trial concluded that prophylactic ICD implantation in symp-
tomatic patients with nonischemic heart failure did not offer a significantly lower 
long-term rate of death from any cause when compared to standard clinical care but 
decreased the incidence of SCD by 50% [32].
ICD implantation remains the main therapy in preventive management for 
DCM patients with impaired LV function, who run a high risk of fatal arrhythmias. 
Guidelines, as well as the Expert Consensus Statement, recommend an ICD implan-
tation in DCM patients with an LMNA gene mutation and risk factors such as NSVT 
observed during monitoring, male sex, truncating mutations (class IIa, level B), and 
an LVEF <45%, which is a higher cutoff value than used in heart failure population 
guidelines [22, 33].
In addition, a primary-prevention ICD should be considered in DCM patients 
with both an arrhythmogenic phenotype and a family history of SCD or ventricu-
lar arrhythmias, irrespective of their LVEF or LV end-diastolic diameter, as they 
compose a high-risk group for major arrhythmic events and SCD [14]. However, 
in individual cases, it can be challenging to determine in which particular patients 
the benefits of ICD implantation would outweigh the risks. The DEFINITE study 
(Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) random-
ized 458 patients with nonischemic DCM (LVEF <36%) and premature ventricular 
complexes or nonsustained VT, between standard medical therapy and ICD implan-
tation. SCD by arrhythmias during a mean follow-up of 29 months was far fewer 
in the ICD group, proving the efficacy of defibrillation [34]. Yet, the use of LVEF 
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alone is not always helpful in determining which patients would most benefit from 
an ICD. This was made clear in the Oregon and Maastricht Registries, in which 80% 
of SCD victims had an LVEF >35% [35, 36].
CRT is recommended in patients with sinus rhythm, NYHA class III/IV heart 
failure, LVEF ≤35%, and QRS >120 ms and/or evidence of mechanical dyssyn-
chrony. It has been shown to offer great survival benefits as well as improvement 
of LV function in DCM patients [37]. This has been observed especially in women, 
who seem to benefit more than men from CRT [38]. Furthermore, it has been 
proven that in patients with nonischemic DCM with an LVEF ≤30%, NYHA class 
II, and QRS duration ≥130 ms, CRT-D device implantation was also beneficial in 
reducing the risk of death or heart failure when compared with defibrillation only 
[39]. On the other hand, patients with low LVEF heart failure and permanent atrial 
fibrillation do not seem to derive extra benefit from a CRT-D device compared with 
standard ICD treatment, as suggested by the Resynchronization for Ambulatory 
Heart Failure Trial (RAFT) trial [40]. Of interest in DCM patients, LGE was 
proven to be a strong, independent predictor of arrhythmic events and was sug-
gested to improve risk stratification for SCD and better identify the need for ICD 
therapy [41].
Decisions about ICD therapy should incorporate genetic factors. In patients with 
mutations, i.e. LMNA mutations, the conventional LVEF-threshold based guide-
lines for ICD do not apply. In fact, an ICD may be considered for a patient with 
higher LVEF thresholds [26, 42]. Regarding FLNC mutations, 20% of patients with 
a primary-prevention ICD who carry the mutation had an appropriate ICD shock, 
much higher than in unselected DCM populations [43]. Appropriate ICD shocks are 
also more likely in PLN carriers, especially in R14del variant, along with a family 
history of SCD before the age of 50 years compared to those who do not carry the 
mutation [44]. These findings support the hypothesis that genetic factors should be 
considered early in the disease progression.
The CMR-Guide (Cardiac Magnetic Resonance Guided Management of Mild-
Moderate Left Ventricular Systolic Dysfunction) trial, which is expected to be 
completed in 2020, is randomizing ischemic and nonischemic cardiomyopathy 
patients with an LVEF between 36 and 50% and presence of LGE to either an ICD or 
an implantable loop recorder in an attempt to determine whether LGE is a sufficient 
marker alone or whether genetic characterization is also necessary in risk stratifica-
tion. In general, a polyparametric integration is being introduced in the primary 
prevention of SCD through ICD implantation in DCM patients that includes family 
history of SCD, LVEF, late gadolinium enhancement, and possibly genetic param-
eters [45].
3. Future perspectives
The evaluation and treatment of hereditary DCM constitutes an emerging 
field. Still, risk stratification regarding SCD is based on general knowledge. Larger 
registries and long-term follow-up may elucidate more specific risk markers associ-
ated with genotypes in addition to phenotype.
4. Conclusion
Hereditary DCM is a heterogeneous condition, which may lead to advanced 
HF as well as SCD. Risk stratification and preventive management strategies are 
challenging. Many factors must be considered in the management of patients with 
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hereditary DCM. Gene mutations are surfacing and have already been proven to 
play a very significant role in clinical decisions. Moreover, based on new data and 
studies, the profile of each DCM patient tends to be better understood. As a result, 
both therapy and prevention evolve and ameliorate in a way that will become indi-
vidualized. ICDs are lifesaving but their role in different genotypic settings remains 
to be elucidated.
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Acronyms and Abbreviations
ACE angiotensin converting enzyme
ARB angiotensin receptor blocker
AR-DCM arrhythmogenic dilated cardiomyopathy
ARVC arrhythmogenic right ventricular cardiomyopathy
CMR cardiac magnetic resonance
CRT cardiac resynchronization therapy
CRT-D cardiac resynchronization therapy defibrillator
DCM dilated cardiomyopathy
ICD implantable cardioverter defibrillator
LGE late gadolinium enhancement
LMNA lamin A/C
LV left ventricle
LVEF left ventricular ejection fraction
NSVT nonsustained ventricular tachycardia
NYHA New York Heart Association
RAAS renin-angiotensin-aldosterone system
PLN phospholamban
RBM20 RNA binding motif protein 20
SCD sudden cardiac death
SCN5A sodium voltage-gated channel alpha subunit 5
TTN titin
VF ventricular fibrillation
VT ventricular tachycardia
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